FOF/VC  BioCrossroads

http://www.biocrossroads.com





     Office Locations:

300 N. Meridian St., Suite 950
Indianapolis, IN 46204
Phone: 317-238-2450
Fax: 317-238-2451

 

Stages:

  • Early
  • Seed


 

Industries:

  • Food & Agriculture
  • Information Technology
  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    BioCrossroads is a collaborative effort among Indiana's corporate community, research universities, and public sector to grow the state's life sciences sector. BioCrossroads initiative seeks to strengthen Indiana's life science base by encouraging commercialization efforts, expanding access to capital, and supporting new business formation. Among several initiatives, the organization established in 2003 the Indiana Future Fund, a $73 million fund-of-funds managed by Credit Suisse. In the fund-of-funds structure, investments are made in venture capital funds, which then invest directly into companies. Additionally, BioCrossroads has established the $6 million, return-driven Indiana Seed Fund, launched in June 2005, and managed by BioCrossroads. The Seed Fund provides working capital in the range of $50,000-$500,000 to promising Indiana life sciences companies at the preliminary stages of operation. In December 2009, the $58 million INext Fund, a venture capital fund of funds, was established with institutional investors Eli Lilly and Company, Indiana State Teachers Retirement Fund, Indiana University, Purdue University, University of Notre Dame and Richard M. Fairbanks Foundation. BioCrossroads organized the fund and Credit Suisse manages it. BioCrossroads formed the Indiana Seed Fund II in early 2012. The Indiana Seed Fund II is an $8 million early-stage life sciences venture fund focused on identifying, creating and developing the next generation of leading Indiana-based companies. Managed by BioCrossroads, the Fund is a follow-on to Indiana Seed Fund I. The Fund makes investments of up to $1 million in early-stage biotechnology, pharmaceutical, medical device, diagnostic, ag-biotech and health information technology products and platforms and will continue to focus on forming promising companies around innovative ideas.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Brenda Bratton
    Brian Stemme Project Director
    Chris Eckerle Project Director
    David L. Johnson President and CEO
    Julie Routt Office manager

     

    Portfolio companies include:


      AgeneBio
        web link


      Allinaire
        web link


      CS-Keys
        web link


      Endocyte
        web link


      Fast Diagnostics
        web link


      FlowCo
        web link


      ImmuneWorks
        web link


      SonarMed
        web link


     

    Recent News: